Sjögren Syndrome with Cutaneous Vasculitis: When Glucocorticoids Don't Reach the ESSDAI Target
Clinical scenario
This protocol applies to patients with Sjögren syndrome presenting with cutaneous vasculitis as a manifestation of active systemic disease. Management of systemic involvement in this setting is tailored to organ-specific severity as defined by the ESSDAI framework.
Previous line — failure condition
The initial treatment approach for systemic cutaneous vasculitis used glucocorticoids. Escalation to this protocol is indicated when glucocorticoids did not achieve a reduction of ≥3 points in the global ESSDAI score — the threshold that defines a meaningful therapeutic response in systemic Sjögren syndrome.
Next-line approach (partial — full protocol below)
When glucocorticoids are insufficient, the next step involves immunosuppressive therapy employed as a glucocorticoid-sparing strategy. The choice of agent is informed by the individual patient's characteristics and tolerability…
Treatment goal
The defined target is a reduction of ≥3 points in the global ESSDAI score, consistent with consensus recommendations for measuring therapeutic response in systemic Sjögren syndrome.
References
DOI: 10.1136/annrheumdis-2019-216114
- Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions.
- The best indication is probably for symptoms linked to cryoglobulinemic-associated vasculitis.
- The lack of head-to-head studies comparing the efficacy and safety profile of immunosuppressive agents in primary SjS-2002 (leflunomide, methotrexate, azathioprine, mycophenolate, cyclophosphamide) does not permit a recommendation on the use of one agent over another, except when patient characteristics or comorbidities are considered with respect to the safety profile.
- With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of >=3 points in the global ESSDAI score.
View source ↗